DE602005009366D1 - Kombination aus tenofovir, ritonavir und tmc114 - Google Patents

Kombination aus tenofovir, ritonavir und tmc114

Info

Publication number
DE602005009366D1
DE602005009366D1 DE602005009366T DE602005009366T DE602005009366D1 DE 602005009366 D1 DE602005009366 D1 DE 602005009366D1 DE 602005009366 T DE602005009366 T DE 602005009366T DE 602005009366 T DE602005009366 T DE 602005009366T DE 602005009366 D1 DE602005009366 D1 DE 602005009366D1
Authority
DE
Germany
Prior art keywords
tenofovir
ritonavir
combination
tmc114
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005009366T
Other languages
English (en)
Inventor
Richard Marinus Hoetelmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Publication of DE602005009366D1 publication Critical patent/DE602005009366D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005009366T 2004-07-08 2005-07-08 Kombination aus tenofovir, ritonavir und tmc114 Expired - Fee Related DE602005009366D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103256 2004-07-08
PCT/EP2005/053266 WO2006005720A1 (en) 2004-07-08 2005-07-08 Combination of anti-hiv reverse transcriptase and protease inhibitors

Publications (1)

Publication Number Publication Date
DE602005009366D1 true DE602005009366D1 (de) 2008-10-09

Family

ID=34929311

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005009366T Expired - Fee Related DE602005009366D1 (de) 2004-07-08 2005-07-08 Kombination aus tenofovir, ritonavir und tmc114

Country Status (19)

Country Link
US (1) US20070208009A1 (de)
EP (1) EP1765337B1 (de)
JP (1) JP2008505870A (de)
CN (1) CN1984654A (de)
AT (1) ATE406161T1 (de)
AU (1) AU2005261701A1 (de)
BR (1) BRPI0513051A (de)
CA (1) CA2572551A1 (de)
DE (1) DE602005009366D1 (de)
DK (1) DK1765337T3 (de)
ES (1) ES2313394T3 (de)
HR (1) HRP20080612T3 (de)
MX (1) MXPA06014930A (de)
NZ (1) NZ551841A (de)
PL (1) PL1765337T3 (de)
RU (1) RU2368380C2 (de)
SI (1) SI1765337T1 (de)
WO (1) WO2006005720A1 (de)
ZA (1) ZA200700176B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814547A1 (de) * 2004-11-16 2007-08-08 Boehringer Ingelheim International Gmbh Verfahren zur behandlung einer hiv-infektion durch gleichzeitige verabreichung von tipranavir und darunavir
WO2009056818A1 (en) * 2007-10-29 2009-05-07 Cipla Limited Novel antiretroviral combination
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
CN102876714A (zh) * 2011-09-07 2013-01-16 深圳市易瑞生物技术有限公司 用慢病毒检测hiv耐药表型
WO2013057469A1 (en) * 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
CN104884063A (zh) * 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物
IN2013MU01749A (de) * 2013-05-15 2015-06-26 Cipla Ltd
MX2016002560A (es) * 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
EP3129009A1 (de) * 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Einheitsdosisform mit emtricitabin, tenofovir, darunavir und ritonavir
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
US10213507B2 (en) * 2017-03-10 2019-02-26 The Florida International University Board Of Trustees Compositions and methods for treating HIV-associated neurocognitive disorders
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors

Also Published As

Publication number Publication date
BRPI0513051A (pt) 2008-04-22
US20070208009A1 (en) 2007-09-06
ES2313394T3 (es) 2009-03-01
ATE406161T1 (de) 2008-09-15
ZA200700176B (en) 2008-04-30
SI1765337T1 (sl) 2009-02-28
WO2006005720A1 (en) 2006-01-19
AU2005261701A1 (en) 2006-01-19
JP2008505870A (ja) 2008-02-28
PL1765337T3 (pl) 2009-02-27
NZ551841A (en) 2009-04-30
RU2368380C2 (ru) 2009-09-27
CN1984654A (zh) 2007-06-20
HRP20080612T3 (en) 2009-01-31
RU2007104774A (ru) 2008-08-20
EP1765337B1 (de) 2008-08-27
CA2572551A1 (en) 2006-01-19
MXPA06014930A (es) 2007-02-28
EP1765337A1 (de) 2007-03-28
DK1765337T3 (da) 2009-01-05

Similar Documents

Publication Publication Date Title
ATE406161T1 (de) Kombination aus tenofovir, ritonavir und tmc114
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
CY1107419T1 (el) Προφαρμακα αντι-ιικων μεσων απο πιπεραζινη και υποκατεστημενη πιπεριδινη
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
PT1318791E (pt) Composicao farmaceutica semi-solida de isotretinoina
MXPA05002814A (es) Formulacion para agentes lipofilicos.
SE0102315D0 (sv) Compounds
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
SE0301700D0 (sv) Novel compounds
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
NO20045323L (no) Antistoffer
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
WO2006034001A3 (en) Methods of treating hiv infection
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE60311665D1 (de) Pharmazeutische zusammensetzungen
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
AP2001002369A0 (en) Pharmaceutical complex.
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee